Metastatic cancer is almost always terminal, and more than 90% of cancer deaths result from
metastatic disease. Combating cancer metastasis and post-therapeutic recurrence …

The vascular endothelial growth factor (VEGF) pathway has been recognized as a key
mediator of angiogenesis to support tumorigenesis. Multiple therapeutic agents targeting …

Background Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …

Background Cetuximab and bevacizumab have both been shown to improve outcomes in
patients with metastatic colorectal cancer when added to chemotherapy regimens; however …

Supramolecular hydrogels confer control over structural properties in a reversible, dynamic,
and biomimetic fashion. The design of supramolecular hydrogels with an improved structural …

Monoclonal antibodies (mAbs) have become a cornerstone in the therapeutic guidelines of
a wide range of solid tumors. The targeted nature of these biotherapeutics has improved …

All patients with metastatic lung, colorectal, pancreatic or head and neck cancers who
initially benefit from epidermal growth factor receptor (EGFR)-targeted therapies eventually …

The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR)
pathway is activated in the majority of human cancers. This pathway is known to play a key …

The epidermal growth factor receptor (EGFR) is a cell-surface receptor belonging to ErbB
family of tyrosine kinase and it plays a vital role in the regulation of cell proliferation, survival …

Overexpression of human epidermal growth factor receptor type 2 (HER2) in breast cancer
is associated with decreased overall survival. Trastuzumab, a humanized monoclonal …